Pirfenidone: A novel agent for the treatment of idiopathic pulmonary fibrosis;Pirfenidona: Un agente nuevo para el tratamiento de fibrosis pulmonar idiopática

Annals of Pharmacotherapy

Volumn 47, Issue 3, 2013, Pages 361-367

  Potts, Jason ^a   Yogaratnam, Dinesh ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MORTALITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; STEVENS JOHNSON SYNDROME; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC EPIDERMAL NECROLYSIS; WALKING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES;

EID: 84875167034     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R337     Document Type: Article

References (20)

1. King T Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-61.
2. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-6.
3. Raghu G, Collard HR, Egan J, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
4. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011;140: 221-9.
5. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:588-94.
6. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77.
7. InterMune. A randomized, double-blind, placebo controlled, phase 3 study of the efficacy and safety of pirfenidone in patients with idiopathic pulmonary fibrosis (ASCEND trial). NLM Identifier: NCT. http://clinicaltrials. gov/ct2/show/NCT01366209 (accessed 2013 Feb 8).
8. Jackson RM, Gomez-Marin O. Development and utility of pirfenidone in the treatment of idiopathic pulmonary fibrosis: review of preclinical science and recent clinical trials. Transplant Res Risk Manage 2011;3:55-63.
9. Carter NJ. Pirfenidone: in idiopathic pulmonary fibrosis. Drugs 2011;71: 1721-32.
10. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590:400-8.
11. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-b gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 291:367-73.
12. Shi S, Wu J, Chen H, et al. Single-and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 2007;47:1268-76.
13. Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009;22:279-85.
14. InterMune. Esbriet (pirfenidone): EU summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002154/WC500103049.pdf (accessed 2012 Oct 1).
15. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999;159:1061-9.
16. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled, trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7.
17. Nagai S, Hamada K, Shigematsu MD, Taniyama M, Yamauchi, S. Open label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002;41:1118-23.
18. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9.
19. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
20. Raghu G, Collard H, Anstrom J, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care 2012;185:1044-8.